U2AF1 mutation
|
AML
|
U2AF1 mutation
|
AML
|
CA-4948 Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks (NewC2)
|
CA-4948 Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks - (New C3)
|
U2AF1 mutation
|
MDS
|
U2AF1 mutation
|
MDS
|
CA-4948 Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks (NewC2)
|
CA-4948 Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks - (New C3)
|
U2AF1 mutation
|
AML
|
U2AF1 mutation
|
AML
|
cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials
|
cytarabine / daunorubicin liposomal formulation Resistant: C3 – Early Trials
|
U2AF1 mutation
|
AML
|
U2AF1 mutation
|
AML
|
cytarabine Resistant: C3 – Early Trials
|
cytarabine Resistant: C3 – Early Trials
|
U2AF1 mutation
|
MDS
|
U2AF1 mutation
|
MDS
|
azacitidine Resistant: C3 – Early Trials
|
azacitidine Resistant: C3 – Early Trials
|
U2AF1 mutation
|
MDS
|
U2AF1 mutation
|
MDS
|
decitabine Resistant: C3 – Early Trials
|
decitabine Resistant: C3 – Early Trials
|
U2AF1 mutation
|
AML
|
U2AF1 mutation
|
AML
|
venetoclax + ABBV 075 Sensitive: C3 – Early Trials
|
venetoclax + ABBV 075 Sensitive: C3 – Early Trials
|